Advances in the Mechanism and Treatments of Parkinson's Disease, are you ready?
- Epidemiology of Parkinson's disease and trend analysis of disease burden
- Research progress on the mechanism of Parkinson's disease
- Clinical guidelines and standards for Parkinson's disease
- Tracking of the latest global prevention & treatment strategies and technical progress of Parkinson's disease
- Global Parkinson's disease drug BD deals tracking during the past 5 years
- An innovative biotech roadshow
Event details
|
DATE Wednesday, Sep 17, 2025 VENUE Online Webex / Zoom TIME 8:00 – 9:00 Berlin time (CET) 14:00 – 15:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Sep 17, 2025 |
PRESENTERS Lingling Cao, CEO & Founder Zhang Ran, Medical advisor REGISTER +86 21 5386 3003 info@lingmed.cn |
Agenda
| CET 8:00 - 8:30 | Advances in the Mechanism and Treatments of Parkinson's Disease |
by Zhang Ran, Medical advisor (Chinese) |
| CET 8:30 - 8:35 | Linkedbio services & projects introduction | by Lingling Cao (English) |
| CET 8:35 - 8:55 | An innovative biotech roadshow | by Guest speaker (English) |
| CET 8:55 – 9:00 | Q&A | (English & Chinese) |
Presenters
 |
Zhang Ran Medical advisor China Pharmaceutical University master HealthShare Management and Consulting Co., Ltd Co-founder 20 years of experience in new drug development. Engaged in new drug research and development in Yangtze River Pharmaceutical Group、Beijing Kawin Technology Share-Holding Co., Ltd.、Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. Co-founded HealthShare in 2016. Serve a number of listed pharmaceutical enterprises. Mainly engaged in research and development pipeline strategic planning, new drug project evaluation, research and development management. |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |